Nephros (NEPH) Gains from Investment Securities (2014 - 2020)

Nephros' (NEPH) quarterly Gains from Investment Securities came in at -$187000.0 in Q3 2020, down 98.94% year-on-year from -$17.6 million in Q4 2019, and down 345.24% quarter-over-quarter from -$42000.0 in Q1 2020.

Nephros (NEPH) Gains from Investment Securities (2014 - 2020) Analysis & Trends

Nephros' Gains from Investment Securities history runs 4 years deep, the most recent figure standing at -$187000.0 for Q3 2020.

  • On a quarterly basis, Gains from Investment Securities fell 98.94% year-over-year to -$187000.0 in Q3 2020; TTM through Dec 2020 was -$229000.0, a 46.79% decrease from a year earlier, with the FY2020 full-year figure at -$229000.0, down 46.79% from the prior year.
  • Gains from Investment Securities fell to -$187000.0 in Q3 2020 per NEPH's latest filing, from -$42000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at -$9000.0 in Q2 2019 and bottomed at -$187000.0 in Q3 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Intuitive Surgical 126.25 Bn 121.03 Bn 1.96 Bn
2 Becton Dickinson 44.77 Bn 43.96 Bn 2.15 Bn
3 Alcon 32.95 Bn 31.29 Bn 1.53 Bn
4 Medline 32.87 Bn 30.63 Bn 1.84 Bn
5 Resmed 29.48 Bn 27.82 Bn 890.98 Mn
6 West Pharmaceutical Services 23.51 Bn 23.07 Bn 329.20 Mn
7 Solventum 14.01 Bn 13.45 Bn 1.10 Bn
8 Cooper Companies 13.77 Bn 13.63 Bn 735.40 Mn
9 Align Technology 12.05 Bn 10.99 Bn 736.59 Mn
10 Nephros 36.20 Mn 32.18 Mn 2.99 Mn

Historic Data

Download Data
DateValue
Sep 30, 2020 -187,000.00
Sep 30, 2020 -187,000.00
Mar 31, 2020 -42,000.00
Mar 31, 2020 -42,000.00
Dec 31, 2019 -43,000.00
Dec 31, 2019 -43,000.00
Sep 30, 2019 -94,000.00
Sep 30, 2019 -94,000.00
Jun 30, 2019 -9,000.00
Jun 30, 2019 -9,000.00
Mar 31, 2019 -10,000.00
Mar 31, 2019 -10,000.00
Sep 30, 2015 -2.29 Mn
Sep 30, 2015 -2.29 Mn
Jun 30, 2015 1.20 Mn
Jun 30, 2015 1.20 Mn
Mar 31, 2015 -1.01 Mn
Mar 31, 2015 -1.01 Mn
Dec 31, 2014 270,000.00
Dec 31, 2014 270,000.00